Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease

NCT07224360 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.

NCT NCT07224360
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07224360 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease
Lead sponsor
CSL Behring
Phase
Phase 2
Overall status
Recruiting
Start date
February 2, 2026
Completion date
June 29, 2028
Enrollment
63 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease